Bio Products Laboratory Ltd.

FORT LEE, N.J., Nov. 1, 2023 /PRNewswire/ -- KEDPLASMA, a leader in the collection of highquality plasma, is proud to announce a comprehensive remodeling initiative aimed at enhancing the experience of its donors and raising the standard of excellence in its collection centers. Plasma collected by KEDPLASMA is used by its parent company Kedrion Biopharma, a global player in the production and distribution of plasma-derived therapies to treat patients with rare and serious conditions. Continue Reading In 2022, Kedrion Biopharma and UK-based Bio Products Laboratory joined forces, adding BPL's 29 plasma collection centers to the centers operated by KEDPLASMA. As a result, the company will temporarily close several of its BPL-branded locations for remodeling and facility enhancement. KEDPLASMA Announces Nationwide Facility Remodeling Project Post this "We are thrilled to invest in these upgrades, which mark a significant milestone in our ongoing efforts to deliver unparalleled donor experiences," said Federico Latini, Chief Executive Officer of KEDPLASMA. "Donors are at the heart of everything we do, and we believe these renovations will elevate their enjoyment and satisfaction when interacting with us." Stough Development Corporation will partner with KEDPLASMA on the project. "The remodeling projects will involve significant upgrades to the interior and exterior of the facilities, including modernized aesthetics, improved accessibility, and state-of-the-art amenities while consolidating all centers under the KEDPLASMA brand." Said Scott Stough, CEO of Stough Development Corporation. "The goal is for donors to feel safe and comfortable during their donation." "As we embark on this exciting chapter, we thank our loyal donors, partners, and stakeholders for their ongoing support" said Ugo Di Francesco, Chief Executive Officer of Kedrion SpA. "Donors stand at the beginning of a bridge between patients and the treatments available for them on the other side. These treatments would not be available without them. We look forward to unveiling the transformed BPL Plasma centers to KEDPLASMA centers soon." KEDPLASMA donors affected by the closures should visit nearby operating locations during this time. KEDPLASMA will consistently update its website () with the latest information on the remodeling progress and reopening dates. About KEDPLASMA KEDPLASMA collects and procures high-quality plasma through a capillary network of plasma centers in more than 70 locations in the United States and 5 in the Czech Republic for its parent company, Kedrion Biopharma, a global biopharmaceutical company, which produces plasma-derived medicinal products treating rare diseases, disorders, and conditions such as Hemophilia and Immunodeficiencies. Kedrion's portfolio includes 37 plasma-derived products which are distributed in over 100 countries. About Stough Development Corporation Stough Development Corporation is a 3rd third-generation family business specializing in developing medical, office, and retail properties. Stough is a full-service real estate company based in Cincinnati, OH, that creates, builds, and manages state-of-the-art medical facilities across the US with holdings in 24 states. In addition to construction and development, Stough has worked in the plasma industry for over 60 years and has remodeled or developed over 70 Plasma centers. Contact Information: Sandy Sklareski Communications Manager [email protected] 551-255-6557 SOURCE Kedrion Biopharma

Global biopharma company encourages education and awareness around a rare bleeding disorder. FORT LEE, N.J., Oct. 10, 2023 /PRNewswire/ -- Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, is proud to recognize the fourth Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2023. This day helps bring awareness to a rare bleeding disorder, the patients it impacts, their challenges, and the treatments that can help. Continue Reading Factor X Day was launched on 10/1020 by U.K.-based Bio Products Laboratory (BPL). In 2022, Kedrion joined forces with BPL. The new Kedrion is a global player in plasma derivatives and rare disease medicines, employing more than 5,000 people worldwide. Kedrion Biopharma is proud to recognize the fourth Hereditary Factor X (10) Deficiency Awareness Day on October 10, 2023 Tweet this About one in a million people have hereditary factor X deficiency, which causes unusual or excessive bleeding or bruising, heavy menstrual bleeding in women, painful or swollen joints, nose bleeds, and bleeding gums. Although the disorder is ultra-rare, some patients with severe factor X deficiency could experience life-threatening complications like bleeding in the brain or stomach. Because symptoms vary, patients may suffer for years before being diagnosed. A simple blood test can determine whether someone has the disorder and can be treated with plasma-based treatments. John, one of the oldest known patients with severe hereditary factor X deficiency at age 51, says it best. "Since being diagnosed when I was a year old, I have had to go to the hospital about 150 times for transfusions of fresh frozen plasma to treat bleeds that were not controlled by themselves. As someone living with hereditary factor X deficiency, I want everyone to be more aware of this rare disease and why it is so important to get care and treatment." "We are excited for the first Hereditary Factor X Deficiency Awareness Day since Kedrion joined forces with Bio Products Laboratory in 2022," said Bob Rossilli, Chief Commercial Officer for Kedrion Biopharma. "With over 60 years of combined expertise across the United Kingdom, United States, and Italy, we are delighted to continue raising awareness for hereditary factor X deficiency and providing therapies to support patients, their caregivers, and families on the journey from diagnosis to treatment." Kedrion is committed to providing therapies for rare diseases to improve patients' health as they manage bleeding disorders like hereditary factor X deficiency. To learn more about hereditary factor X deficiency, visit . About Kedrion Kedrion Biopharma is a global biopharmaceutical company that collects and fractionates blood plasma to produce and distribute plasma-derived therapies for use in treating and preventing serious diseases, disorders, and conditions like plasminogen deficiency, hereditary factor X deficiency, and hemophilia. Its portfolio of 37 life-saving products is distributed in over 100 countries. kedrion.com Contact Information: Sandy Sklareski Communications Manager [email protected] 551-255-6557 SOURCE Kedrion Biopharma

SOUTHLAKE, Texas--( BUSINESS WIRE )--ImmunoTek Bio Centers LLC has hired Marvin Dyke as President. Dyke comes to ImmunoTek with solid experience in the plasma industry, having served six years with Bio-Products Laboratory (BPL) in a variety of executive roles and, most recently, as President of BPL Plasma. In the president role within ImmunoTek, Dyke will be responsible for growing the existing core business of developing plasma centers for customers and expanding the company's industry footprint as a direct supplier to fractionation companies, all while ensuring ImmunoTek maintains its impressive regulatory track record. Some of Dyke’s notable contributions while at BPL Plasma include the development of 20 new plasma centers; the divestiture of 25 centers to a major fractionator, and the divestiture of BPL Plasma to its current owner in 2022. Before joining BPL Plasma, Marvin was the Managing Partner at MPower Insight, a management consulting firm he founded in 2015. He and his partners helped late-stage startups and family-operated businesses tackle their next stage of growth. Before that, Marvin spent 13 years with Thermo Fisher Scientific in general management, global finance, and operational leadership roles. He served in two expatriate assignments in the U.K. and The Netherlands. During his career with Thermo Fisher, he gained extensive experience with business consolidation and offshoring, clinical packaging, and cold chain logistics. Marvin earned a Bachelor of Science degree in Economics with a minor in Systems Engineering from the United States Military Academy at West Point, and a Master of Business Administration from the University of Virginia’s Darden Graduate School of Business. Jerome Parnell III, CEO and Board Member of ImmunoTek, stated, “Our organization continues to expand and thrive as we are methodically making an impact within the global plasma industry. We created a thoughtful multi-year strategic plan, which also includes investing in our leadership infrastructure and systems. Most of those refinements are already in progress.” Parnell III continued, “As part of that infrastructure investment, Marvin will have an internal focus and the responsibility of leading and growing our core existing business. We are excited to have him join our leadership team.” ABOUT IMMUNOTEK BIO CENTERS, LLC ImmunoTek Bio Centers LLC is the world's largest and fastest-growing independent plasma collection center operator. ImmunoTek is a global leader in developing a reliable plasma supply chain for international biotech companies and partnering with organizations for ancillary projects related to blood-plasma collection. Since its inception in 2013, ImmunoTek has built and operated more than 70 plasma collection centers, most of which have achieved or are in the process of attaining U.S. FDA licensure and European certification. ImmunoTek currently has centers operating in 20 states, with 20 additional centers under development and planning underway for more than 40 additional sites over the next three years. For more information, visit ImmunoTek.com